sorafenib has been researched along with artenimol in 5 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (artenimol) | Trials (artenimol) | Recent Studies (post-2010) (artenimol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 53 | 0 | 48 |
| 6,520 | 730 | 5,251 | 1,419 | 279 | 987 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Duan, X; Lv, Y; Wang, Z; Zhao, Y | 1 |
| Guo, D; Hou, C; Liu, T; Wang, S; Yu, X | 1 |
| Cui, Z; Jiang, T; Li, C; Li, L; Li, S; Ma, J; Qin, T; Shi, H; Wang, H; Yu, G | 1 |
| Cui, Z; Jiang, T; Li, C; Li, L; Li, S; Ma, J; Qin, T; Shi, H; Tang, T; Wang, H; Xu, W; Zhou, H | 1 |
1 review(s) available for sorafenib and artenimol
| Article | Year |
|---|---|
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
4 other study(ies) available for sorafenib and artenimol
| Article | Year |
|---|---|
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Reactive Oxygen Species; Receptors, LDL; Sorafenib | 2019 |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Sorafenib; Up-Regulation | 2020 |
Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
Topics: Animals; Antineoplastic Agents; Artemisinins; Depression, Chemical; Drug Synergism; Drug Therapy, Combination; Energy Metabolism; Female; Ferroptosis; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Sorafenib | 2022 |
Ferroptosis plays an essential role in the antimalarial mechanism of low-dose dihydroartemisinin.
Topics: Animals; Antimalarials; Artemisinins; Cell Death; Female; Ferroptosis; Humans; Malaria; Mice; Mice, Inbred C57BL; Parasites; Piperazines; Reactive Oxygen Species; Sorafenib | 2022 |